Inovio Pharmaceuticals, Inc.

LSE:0A43 Stock Report

Market Cap: US$106.2m

Inovio Pharmaceuticals Valuation

Is 0A43 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A43 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0A43 ($4.17) is trading below our estimate of fair value ($125.07)

Significantly Below Fair Value: 0A43 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A43?

Key metric: As 0A43 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0A43. This is calculated by dividing 0A43's market cap by their current book value.
What is 0A43's PB Ratio?
PB Ratio1.4x
BookUS$73.54m
Market CapUS$106.23m

Price to Book Ratio vs Peers

How does 0A43's PB Ratio compare to its peers?

The above table shows the PB ratio for 0A43 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average37.5x
ETX e-therapeutics
1.9xn/aUK£52.6m
FARN Faron Pharmaceuticals Oy
130.1x17.3%UK£149.1m
PRTC PureTech Health
1.6x-13.0%UK£409.9m
BVXP Bioventix
16.3xn/aUK£195.7m
0A43 Inovio Pharmaceuticals
1.4x26.2%US$106.2m

Price-To-Book vs Peers: 0A43 is good value based on its Price-To-Book Ratio (1.4x) compared to the peer average (37.5x).

Price to Book Ratio vs Industry

How does 0A43's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.46m
VAL ValiRx
0.6xn/aUS$2.78m
No more companies available in this PB range
0A43 1.4xIndustry Avg. 2.9xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0A43 is good value based on its Price-To-Book Ratio (1.4x) compared to the UK Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is 0A43's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A43 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0A43's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A43 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.17
US$10.67
+155.8%
51.0%US$18.00US$5.00n/a6
Nov ’25US$5.50
US$15.75
+186.5%
53.9%US$33.00US$7.00n/a6
Oct ’25US$5.68
US$16.75
+195.0%
50.4%US$33.00US$8.00n/a6
Sep ’25US$7.19
US$16.75
+133.0%
50.4%US$33.00US$8.00n/a6
Aug ’25US$10.10
US$18.92
+87.3%
53.4%US$40.00US$9.50n/a6
Jul ’25US$8.36
US$18.92
+126.4%
53.4%US$40.00US$9.50n/a6
Jun ’25US$10.12
US$18.92
+86.9%
53.4%US$40.00US$9.50n/a6
May ’25US$11.64
US$19.25
+65.4%
65.0%US$40.00US$8.00n/a4
Apr ’25US$14.13
US$19.25
+36.2%
65.0%US$40.00US$8.00n/a4
Mar ’25US$9.62
US$18.83
+95.8%
81.1%US$40.00US$4.50n/a3
Feb ’25US$5.45
US$18.93
+247.3%
80.2%US$40.00US$4.80n/a3
Nov ’24US$4.41
US$15.00
+240.1%
60.0%US$24.00US$6.00US$5.502
Oct ’24US$4.78
US$15.00
+214.1%
60.0%US$24.00US$6.00US$5.682
Sep ’24US$5.50
US$15.00
+172.8%
60.0%US$24.00US$6.00US$7.192
Aug ’24US$5.87
US$16.00
+172.8%
35.4%US$24.00US$12.00US$10.103
Jul ’24US$5.58
US$16.00
+186.6%
35.4%US$24.00US$12.00US$8.363
Jun ’24US$7.00
US$16.00
+128.6%
35.4%US$24.00US$12.00US$10.123
May ’24US$9.23
US$16.80
+82.0%
30.9%US$24.00US$12.00US$11.643
Apr ’24US$9.90
US$16.80
+69.7%
30.9%US$24.00US$12.00US$14.133
Mar ’24US$14.51
US$28.00
+92.9%
20.2%US$36.00US$24.00US$9.623
Feb ’24US$20.04
US$28.00
+39.7%
20.2%US$36.00US$24.00US$5.453
Jan ’24US$17.70
US$27.00
+52.5%
19.2%US$36.00US$24.00US$6.154
Dec ’23US$23.46
US$27.00
+15.1%
19.2%US$36.00US$24.00US$4.624
Nov ’23US$25.32
US$36.00
+42.2%
36.5%US$60.00US$24.00US$4.415

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-16.2%

1Y

22.2%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%